US Patent 11548952 Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
Patent 11548952 was granted and assigned to Genmab A/S on January, 2023 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
December 22, 2021
0
Date of Patent
January 10, 2023
0
Patent Applicant
Patent Application Number
17560006
0
Patent Citations
Patent Citations Received
Patent Inventor Names
Brian Elliott
0
Tahamtan Ahmadi
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 11548952 Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.